Studying treatment response in small cell lung cancer with genetic testing
Part of Cancer, Lungs & breathing clinical trials.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have limited or extensive stage small cell lung cancer (confirmed by biopsy).
- You have not yet started any cancer treatment.
- You are willing to provide blood and tumor tissue samples.
- You have measurable tumors that can be tracked.
- Your general health is good (ECOG score 0 or 1, and expected survival at least 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
This study looks at how small cell lung cancer changes over time by testing your blood during your first treatment. They will collect blood samples to see if certain patterns can help predict how well the treatment works.
This trial is for adults with small cell lung cancer where your diagnosis is confirmed by a tissue test. The study looks at molecular (tumor-level) features to help guide treatment choices that may fit you better.
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.